California’s Amgen (Nasdaq: AMGN) has reported third-quarter 2021 financial results showing total revenues increased 4% to $6.71 billion, driven by higher demand.
The positive result, which was partially offset by lower net prices, was a touch higher than analysts had expected, with the Financial Times consensus forecast coming in at $6.68 billion.
Following Generally Accepted Accounting Principles (GAAP), the earnings per share (EPS) figure decreased 3% to $3.31, due to a $400 million licensing-related expense from a collaboration with Kyowa Kirin (TYO: 4151).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze